Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew David Hellmann, Tavi Nathanson, Hira A. Rizvi et al. · Cancer Cell · 2018
Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated with PD-1 plus CTLA-4 blockade, we found that high tumor mutation burden (TMB) predicted improved objective response, durable benefit, and progression-free survival. TMB was independent of PD-L1 expression and the strongest feature associated with efficacy in multivariable analysis. The low response rate in TMB low NSCLCs demonstrates that combination immunotherapy does not overcome the negative predictive impact of low TMB. This study demonstrates the association between TMB and benefit to combination immunotherapy in NSCLC. TMB should be incorporated in future trials examining PD-(L)1 with CTLA-4 blockade in NSCLC.
Cited by 1,094 works. doi:10.1016/j.ccell.2018.03.018
Authors
- Matthew David Hellmann
- Tavi Nathanson
- Hira A. Rizvi
- Ben Creelan
- Francisco Sánchez-Vega
- Arun Ahuja
- Ai Ni
- Jacki B. Novik
- Levi Mark B Mangarin
- Mohsen Abu-Akeel
- Cailian Liu
- Jennifer L. Sauter
- Natasha Rekhtman
- Eliza Chang
- Margaret K. Callahan
- Jamie E. Chaft
- Martin Henner Voss
- Megan Tenet
- Xuemei Li
- Kelly L. Covello
References
- Fast and accurate short read alignment with Burrows–Wheeler transform
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- Mutational heterogeneity in cancer and the search for new cancer-associated genes